BioNTech (BNTX) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for BioNTech (NASDAQ: BNTX):

• 11/9/2026 – BioNTech had its price target lowered by HC Wainwright from $130.00 to $110.00. They now have a “buy” rating on the stock.
• 11/7/2026 – BioNTech was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/4/2026 – BioNTech had its “buy” rating reaffirmed by Bank of America.
• 11/4/2026 – BioNTech had its price target lowered by UBS Group from $135.00 to $125.00. They now have a “buy” rating on the stock.
• 11/4/2026 – BioNTech had its price target lowered by Morgan Stanley from $114.00 to $106.00. They now have an “overweight” rating on the stock.
• 11/4/2026 – BioNTech had its price target lowered by Wells Fargo & Company from $140.00 to $125.00. They now have an “overweight” rating on the stock.
• 10/14/2026 – BioNTech had its price target lowered by Canaccord Genuity Group from $136.00 to $132.00. They now have a “buy” rating on the stock.
• 10/8/2026 – BioNTech is now covered by Argus. They set a “hold” rating on the stock.
• 10/7/2026 – BioNTech had its price target lowered by Morgan Stanley from $115.00 to $114.00. They now have an “overweight” rating on the stock.
• 10/2/2026 – BioNTech had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/16/2026 – BioNTech had its “buy” rating reaffirmed by UBS Group.
• 9/16/2026 – BioNTech was given a new $140.00 price target by Berenberg Bank.

BioNTech Price Performance

Shares of BNTX opened at $85.04 on Friday. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a market capitalization of $21.50 billion, a P/E ratio of -12.41 and a beta of 1.28. The firm has a 50 day moving average of $93.42 and a 200 day moving average of $96.09. The company has a quick ratio of 8.52, a current ratio of 8.55 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction on Friday, October 9th. The stock was sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 807,209 shares of company stock worth $79,246,837. Company insiders own 19.20% of the company’s stock.

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.